Since the start of the Strategic Plan to Address Hepatitis C, more than 164,502 people with hepatitis C have been treated in Spain. Our country’s cure rate is around 95%, making it one of the leading countries in eliminating the disease. Hepatitis D is associated with more rapid progression of liver fibrosis and cirrhosis and an increased risk of liver cancer and death. The problem is that many patients go undiagnosed. This is due in part to limited understanding of the disease and the limited availability of diagnostic methods.
Therefore, Gilead Sciences and the Spanish Association for the Study of the Liver (AEEH) want to promote research projects that will benefit these patients. They once again awarded the “Sixth Edition of the Gilead Hepatitis C and Hepatitis D Epidemiology Micro-Elimination Project Fellowship.”
14 scholarship programs
23 projects were evaluated, 14 of which were awarded scholarships. These individuals will receive a total of €350,000. Among the winning projects, seven are dedicated to the diagnosis and referral of patients with hepatitis C. Another two are devoted to understanding the epidemiology of hepatitis D and five to methods of diagnosing all viral hepatitis.
“The idea of launching a research program that would bring the benefits of proactive testing, improved care and access to treatment immediately to the general population is unparalleled. So we are very happy, proud and satisfied. We believe this is the best way to advance research and public health.” One of the best ways. In addition to achieving goals that would otherwise be unattainable,” he emphasized Manuel Romero, AEEH President.
on the same line, Marissa Alvarez, Executive Officer.Director of Medical Affairs, Gilead Spain” noted, “Gilead’s unwavering commitment to hepatitis patients sets us on a clear path: supporting our scientific research community. Through the six editions of the fellowship programme, different local projects have been developed to assist in the diagnosis and referral of hepatitis C patients. It reinforces our commitment in the new year to learn more about the epidemiology of hepatitis D, which represents an unmet medical need. “
You might also like…